Drug intelligence / Profile preview

3BP-3775

Development stage: Unknown
Lead developer: 3B Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

**3BP-3775** is a development-stage diagnostic radiopharmaceutical that targets the Glucose-dependent Insulinotropic Polypeptide receptor (GIP receptor, GIPR), which is highly expressed in a subset of neuroendocrine tumors (NETs). It is being developed as an alternative radiopharmaceutical treatment for patients with NETs who are ineligible for somatostatin receptor-targeted therapies such as Lutathera. The drug aims to address the unmet need in sstr-negative and Lutathera-ineligible NET patients. The program is led by 3B Pharmaceuticals and has entered early clinical development[1][2][4].

Targets

GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on 3BP-3775.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3BP-3775.

Explore the full profile